Close

Stay informed

Drop us your email and we’ll keep you up-to-date on Medicaid issues.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Letter ·

NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug

On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence Development (CED) for monoclonal antibody treatments for Alzheimer’s disease.

On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence Development (CED) for monoclonal antibody treatments for Alzheimer’s disease. In these comments, NAMD underscored that the proposed coverage determination may have significant financial impacts on state Medicaid programs, and that states must therefore retain the ability to set appropriate Medicaid utilization controls. NAMD also encouraged Congress to explore additional tools to help state Medicaid programs address future high-cost specialty drugs.

Related resources

Stay Informed

Drop us your email and we’ll keep you up-to-date on Medicaid issues.